Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The U.S. government awarded Novavax, Inc. (NASDAQ: NVAX) $1.6 billion in funding to support its COVID-19 vaccine, and the company is confident it has the capability to produce 100 million doses by the end of the year, Novavax CEO Stanley Erck said on CNBC's "Squawk Box.

Novavax CEO Talks $1.6B Federal Funding Win, Ex-FDA Chief Says It's A 'Good Bet'

Regeneron Pharmaceuticals

Novavax Inc. (NASDAQ: NVAX) said on Tuesday that it inked an agreement with the U.S.

U.S. government invests in Novavax and Regeneron Pharmaceuticals under “Operation Warp Speed”

Novavax Inc. (NASDAQ: NVAX) and Regeneron Pharmaceuticals Inc.

Operation Warp Speed Ramps Up With Novavax and Regeneron

Novavax stock rocketed Tuesday after the biotech company nabbed $1.6 billion in government funding for its coronavirus vaccine. Regeneron also inked a manufacturing deal for its drug.

Novavax Stock Nabs $1.6 Billion In Funding And Soars To 4-Year High

"What the coronavirus does is it moves up the timetable for us to have revenue, and quite a bit actually," Novavax CEO Stanley Erck said on CNBC's "Squawk Box."

Novavax—up over 1,800% in 2020—sees big revenue opportunities from potential coronavirus vaccine

The funds will support the rapid development and mass production of the biotech's  coronavirus vaccine candidate, NVX-CoV2373.

Novavax Awarded $1.6 Billion From Operation Warp Speed to Fund COVID-19 Vaccine Program

Novavax lands a massive $1.6 billion award from the federal government's Operation Warp Speed program.

Why Novavax Stock Is Skyrocketing Today

Novavax, Inc. (NASDAQ: NVAX) shares, which were up about 1,900% year-to-date, are seeing further strength after the company's coronavirus vaccine program was shortlisted by the U.S.

Novavax Shares Cross $100 Threshold On $1.6B Federal Funding Award For Coronavirus Vaccine

The feds have committed $1.6 billion to help biotech firm Novavax develop its coronavirus vaccine and produce 100 million doses, potentially starting later this year. The award announced Tuesday is the largest so far from Operation Warp Speed, the Trump administration’s effort to deliver a vaccine by January.

Novavax gets $1.6 billion from government to develop coronavirus vaccine

Novavax Inc. NVAX, -2.69% said Tuesday it has received $1.6 billion in funding from the federal government's accelerated COVID-19 vaccine development program "Operation Warp Speed.

Novavax shares soar 38% premarket on news of $1.6 billion in funding for COVID-19 vaccine candidate

The U.S. government has awarded Novavax Inc $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021.

U.S. government awards Novavax $1.6 billion for coronavirus vaccine

GAITHERSBURG, Md., July  07, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has been selected to participate in Operation Warp Speed (OWS), a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 in 2021. Novavax has been awarded $1.6 billion by the federal government to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

Novavax Announces $1.6 Billion Funding from Operation Warp Speed

AstraZeneca

Gritstone Oncology Inc

iShares Nasdaq Biotechnology ETF

Sanofi

For the most part, biotech and pharmaceutical companies are involved in the lengthy process of getting their drug candidates to market through clinical trials.

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Here's why the company's amazing run on the stock market year to date could continue.

These 3 Things Could Send Novavax's Stock Soaring to New Heights

Frank Czworka appointed SVP, Global Sales

Novavax Announces Updates to Leadership Team

Blue Apron

Inovio Pharmaceuticals

Lululemon Athletica

Nikola

Overstock.com

Peloton

Shopify

Wayfair

Zoom Video

These stocks are ignoring everything from valuation to coronavirus risks, and are instead pushing to new highs

10 High-Risk Stocks Flexing on the Market

Johnson & Johnson

Merck

Moderna

Pfizer

Around a dozen companies are developing a vaccine for the deadly coronavirus disease.

FDA Issues Guidance for Coronavirus Vaccine Developers

I'm up 1,340% in nine months on this investment. Is it time to take some profits?

Should I Sell Novavax Shares?

Royalty Pharma

Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its therapies to treat COVID-19.

Nasdaq's $1.2 trillion biotech index draws Europe's COVID drug hunters

Novavax, Inc. (NASDAQ: NVAX) shares are on a dream run this year amid catalysts including its COVID-19 vaccine program.

Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales

TRI Pointe Group

Unisys

These are the small cap stocks with the best value, fastest growth, and most momentum for July.

Top Small Cap Stocks for July 2020

GAITHERSBURG, Md., June  29, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with responsibility for overseeing Novavax’ manufacturing, process technology, quality and regulatory functions. The Company also announced several leadership promotions:

Novavax Expands Executive Leadership and Announces Key Promotions

Covid-19 vaccine stocks are on fire, but many of them appear to be out over their skis, including the group's hottest name, NVAX stock.
The post Be Careful with Novavax and the Recent Surge in NVAX Stock appeared first on InvestorPlace.

News for Novavax Stock (NVAX)